Decheng Capital
德诚资本
Decheng Capital (德诚资本) is a venture capital fund active in Chinese biotech and life-sciences investing. It appears as a co-lead or co-investor in at least two sizable biopharma deals in elsewhere's corpus: Hangzhou Andao Pharma's $50 million Series B in late 2021, where it followed Gaorong Ventures and Northern Light Venture Capital , and Syneron Bio's $150 million Series B in March 2026, where it co-led with DH VGC alongside a roster of global institutions including ADIA, Temasek's Daming Capital, and Qiming Venture Partners . Beyond these, elsewhere's corpus does not yet cover its vintage, AUM, or full portfolio scope.
AI-generated — may contain errors, please verify.
Coverage
5Y News | Syneron Bio Closes $150 Million Series B Round
Syneron Bio today announced the completion of its Series B funding round.
Gaorong Monthly · December | Gaorong Ventures and Its Frontier Tech / Consumer / Healthcare / Enterprise Service Portfolio Companies Win Multiple Annual Awards
Its technological and innovative capabilities have won recognition.
Hangzhou Andao Pharma Closes $50 Million Series B to Advance Drug Development for Kidney Disease and Cancer
Addressing the enormous unmet clinical needs in nephrology and oncology.
